UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 21, 2020
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
California |
|
|
(State or Other Jurisdiction of Incorporation) |
|
|
001-36747 |
02-0692322 |
|
(Commission File Number) |
(IRS Employer Identification No.) |
|
12744 San Fernando Road, Suite 400 |
|
|
(Address of Principal Executive Offices) |
|
|
|
|
|
(818) 833-5000 |
|
|
(Registrant's Telephone Number, Including Area Code) |
|
|
(Former Name or Former Address, if Changed Since Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ⎕
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⎕
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Common Stock |
|
EYES |
|
Nasdaq |
|
|
Warrants |
|
EYESW |
|
Nasdaq |
|
_____________________________________________________________________________________________
Letter from Nasdaq dated July 21, 2020
On July 21, 2020 The Nasdaq Stock Market (“Nasdaq”) notified Second Sight Medical Products, Inc. (the “Company”), based on the information that the board of directors of the Company had appointed Aaron Mendelsohn, an independent director, to the Company’s compensation committee, that it has determined that the Company complies with Rule 5605(d)(2) (the “Rule”), and this matter is now closed.
As previously disclosed and prior to the Company’s remediation, Nasdaq notified the Company on June 2, 2020 that it did not comply with the compensation committee requirement for continued listing on Nasdaq set forth in the Rule.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 22, 2020
SECOND SIGHT MEDICAL PRODUCTS, INC.
|
/s/ John T. Blake |
By: John T. Blake